Briquilimab was well tolerated in the study. No SAEs or AEs grade 3 were reported. Furthermore, there were no reported AEs related to hair or skin color changes, hypersensitivity, or anemia. Mild ...
No serious adverse events; no grade 3 or higher adverse events reported Initial data from BEACON study expected week of January 6 th, 2025, including 180mg Q8W cohort Company to host conference call ...